Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,305.22 +58.54 (+1.12%) Dow
39,888.73 +330.62 (+0.84%) Nasdaq
16,741.10 +229.92 (+1.39%) Bitcoin USD
66,254.65 +4,673.25 (+7.59%) CMC Crypto 200
1,390.48 +122.54 (+9.67%)
BX Oct 2024 60.000 call
| Previous close | 44.25 |
| Open | N/A |
| Bid | 67.70 |
| Ask | 70.50 |
| Strike | 60.00 |
| Expiry date | 2024-10-18 |
| Day's range | 44.25 - 44.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Insider MonkeyIs Blackstone Inc (NYSE:BX) the Best Financial Dividend Stock Insiders are Buying in 2024?
Insider Monkey has been scouring insider trades this year to see which stocks are seeing increased interest from corporate officers. Amid the market’s broader shift towards defensive, safe stocks that also pay dividends, we saw that insiders are flocking to buy financial and bank dividend stocks like JPMorgan Chase & Co. (NYSE:JPM), Wells Fargo & […]
Business WireBlackstone to Present at Bernstein’s 40th Annual Strategic Decisions Conference
NEW YORK, May 15, 2024--Blackstone (NYSE:BX) announced today that Jon Gray, President and Chief Operating Officer, is scheduled to present at Bernstein’s 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 at 10:00am ET.
Business WireBlackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation
NEW YORK, May 15, 2024--Blackstone (NYSE:BX) today announced the launch of the Blackstone Life Sciences ("Blackstone") portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. Uniquity Bio is emerging from stealth with an FDA acceptance of its Phase 2 investigational new drug ("IND") application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indicatio
